Fig. 5

IHL owned the best response to anti-TNF or anti-integrin therapy a Severity of IHL under endoscopy was not statistically different from other subtypes. b There was no difference in the treatment of glucocorticoids for each subtype. c–d Three subtypes exhibited different response rate to Infliximab or Vedolizumab therapy in GSE73661. e–f Three subtypes exhibited different response rate to Infliximab therapy in GSE16879. g Three subtypes exhibited different response rate to Infliximab or Vedolizumab therapy in FDUHS cohort (IIA n = 1, WIA n = 5, IHL n = 6)